|
시장보고서
상품코드
1812419
근이완제 시장 : 유형별, 클래스별, 투약형별, 투여 경로별, 용도별, 연령층별, 유통 채널별, 최종 사용자별, 제품 유형별, 지역별Muscle Relaxant Drugs Market, By Drug Type, By Drug Class, By Dosage Form, By Route of Administration, By Application, By Age Group, By Distribution Channel, By End User, By Product Type, By Geography |
||||||
근이완제 시장은 2025년에 43억 4,000만 달러, 2032년에는 63억 6,000만 달러에 이르고, 2025년부터 2032년까지의 연평균 성장률(CAGR) 7.1%로 성장할 것으로 예측되고 있습니다.
| 보고 범위 | 보고서 세부정보 | ||
|---|---|---|---|
| 기준 연도 | 2024년 | 2025년 시장 규모 | 43억 4,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2020-2024년 |
| 예측기간 2025-2032년 CAGR : | 7.10% | 2032년 가치 예측 | 63억 6,000만 달러 |
세계 근이완제 시장은 제약 산업의 중요한 부분이며, 근육과 관련된 질병 및 증상에 대한 치료 개입의 광범위한 요구에 대응하고 있습니다.
근이완제는 근육의 긴장을 완화하고 경련을 완화하며 근골격계의 통증을 완화하도록 설계된 다양한 약물 클래스이며, 섬유근통증, 다발성 경화증, 척수 손상, 수술 후 회복 시나리오 등 다양한 병리학 환자에게 유용합니다. 이러한 의약품 화합물은 중추 신경계의 억제, 근섬유의 직접 간섭, 신경근 접합부의 차단 등 다양한 메커니즘으로 기능하여 현대 의료에 필수적인 도구가 되고 있습니다.
시클로벤자푸린이나 바클로펜과 같은 전통적인 약물부터 효능 프로파일이 개선되고 부작용이 완화된 새로운 혁신적인 화합물에 이르기까지 시장은 처방약과 시판약을 모두 포함합니다. 의료 제공업체는 급성 및 만성 근골격계 질환에 대한 종합적인 치료 프로토콜의 일환으로 이러한 치료제에 대한 의존도를 높이고 있으며, 병원, 클리닉 및 외래 시설 전반에서 지속적인 수요를 이끌고 있습니다.
생활 습관과 관련된 근육 장애의 유병률 증가, 인구 역학의 고령화, 통증 관리 옵션에 대한 의식 증가는 시장 확대에 계속 박차를 가하고 있으며, 근이완제를 현대 의료 전달 시스템의 필수 요소로 세계에 놓고 있습니다.
시장 역학
세계의 근이완제 시장은 앉아서 생활하는 생활 방식, 인구의 고령화, 효과적인 치료개입을 필요로 하는 직장과 관련된 상해 발생률 증가 등에 의해 세계적으로 근골격계 장애의 유병률이 상승하고 있는 것을 주요 요인으로써 그 강력한 성장 궤도에 공헌하고 있는 몇 가지 주요 촉진요인에 밀려 고도의 통증 관리 전략에 대한 의료 전문가와 환자의 인식이 높아지면서 부작용이 적고 보다 표적을 좁힌 효과적인 근이완제 시장 개척으로 이어지는 지속적인 의약 기술 혁신이 시장 확대를 크게 뒷받침하고 있습니다. 의료 지출 증가, 처방약에 대한 보험 적용 개선, 신흥국의 전문 의료에 대한 접근 확대가 시장 성장을 더욱 가속화하고 있습니다.
그러나 신흥국 시장은 제품의 상시를 지연시키고 개발 비용을 증가시킬 수 있는 의약품 승인 프로세스를 관리하는 엄격한 규제 프레임워크과 특정 근이완제와 관련된 잠재적인 남용과 의존에 대한 우려 증가가 처방자의 주저나 규제 당국의 감시로 이어지는 등 현저한 억제요인에 직면합니다. 반면에 물리치료, 침술, 비약리학적 개입과 같은 대체 치료법은 시장 침투를 제한할 수 있습니다. 이러한 과제에도 불구하고, 경피 흡수 패치 및 서방형 제형 등 환자의 컴플라이언스 및 치료 성적을 향상시키는 새로운 약물 전달 시스템의 개발을 통해 시장에 큰 비즈니스 기회가 확산되고 있습니다.
본 조사의 주요 특징
- 본 보고서에서는 세계의 근이완제 시장을 상세하게 분석하여 2024년을 기준연도으로 한 예측기간(2025-2032년) 시장 규모(10억 달러)와 연간 평균 성장률(CAGR%)을 제공합니다.
- 또한 다양한 부문에 걸친 잠재적인 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 행렬에 대해 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
- 엔터프라이즈 하이라이트, 제품 포트폴리오, 주요 하이라이트, 업적, 전략 등의 매개변수를 기반으로 전 세계 근육 이완 시장에서 주요 기업 프로파일을 제공합니다.
- 이 보고서의 통찰을 통해 마케팅 담당자와 기업 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전술에 대한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
- 근이완제 세계 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자는 세계 근이완제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 조사의 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 출시/승인
- PEST 분석
- PORTER 분석
- 합병과 인수 시나리오
- 업계 동향
제4장 세계의 근이완제 시장, 약제 유형별, 2020년-2032년
- 골격근 이완제(예: 시클로벤자푸린, 바클로펜 등)
- 신경근 차단제(예: 로크로늄, 석시닐콜린 등)
- 안면근 이완제(주로 보톡스, 디스포트, 제오민 등의 보툴리눔툭신(보톡스) 베이스 제품)
제5장 세계의 근이완제 시장, 약제 클래스별, 2020년-2032년
- 중추성 근이완제
- 말초성 근이완제
제6장 세계의 근이완제 시장, 제형별, 2020년-2032년
- 정제
- 캡슐
- 액체
- 기타(젤, 연고, 스프레이 등)
제7장 세계의 근이완제 시장, 투여 경로별, 2020년-2032년
- 경구
- 비경구(주사)
- 국소
제8장 세계의 근이완제 시장, 용도별, 2020년-2032년
- 근육 경련과 통증 완화
- 근골격계 장애
- 외과 마취
- 기타(예: 섬유근통증 등)
제9장 세계의 근이완제 시장, 연령층별, 2020년-2032년
- 성인
- 소아
- 고령자
제10장 세계의 근이완제 시장, 유통 채널별, 2020년-2032년
- 병원 약국
- 소매 약국
- 온라인 약국
제11장 세계의 근이완제 시장, 최종 사용자별, 2020년-2032년
- 병원
- 재택 케어
- 전문 클리닉
- 기타
제12장 세계의 근이완제 시장, 제품 유형별, 2020년-2032년
- 브랜드
- 제네릭
제13장 세계의 근이완제 시장, 지역별, 2020년-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카
- 북아프리카
- 중앙 아프리카
제14장 경쟁 구도
- Pfizer Inc.
- Tev Pharmaceutical Industries Ltd.
- Ipsen Pharma SA
- Zydus Lifesciences Ltd.
- Neurana Pharmaceuticals Inc.
- Amneal Pharmaceuticals Inc.
- Johnson & Johnson Services Inc.
- Merck & Co., Inc.
- Eisai Co. Ltd.
- Intas Pharmaceuticals Ltd.
- Mallinckrodt PLC
- Endo International plc
- Hoffmann-La Roche AG
- Merz Pharmaceuticals LLC
- Sun Pharmaceutical Industries Ltd
제15장 분석가 추천
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제16장 참고문헌과 조사방법
- 참고문헌
- 조사 방법
- 출판사에 대해
Muscle Relaxant Drugs Market is estimated to be valued at USD 4.34 Bn in 2025 and is expected to reach USD 6.36 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.1% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 4.34 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.10% | 2032 Value Projection: | USD 6.36 Bn |
The global muscle relaxant drugs market represents a critical segment of the pharmaceutical industry, addressing the widespread need for therapeutic interventions in muscle-related disorders and conditions.
Muscle relaxants are a diverse class of medications designed to reduce muscle tension, alleviate spasms, and provide relief from musculoskeletal pain, serving patients across various medical conditions including fibromyalgia, multiple sclerosis, spinal cord injuries, and post-operative recovery scenarios. These pharmaceutical compounds function through different mechanisms, including central nervous system depression, direct muscle fiber interference, and neuromuscular junction blocking, making them indispensable tools in modern medical practice.
The market encompasses both prescription and over-the-counter formulations, ranging from traditional medications like cyclobenzaprine and baclofen to newer innovative compounds with improved efficacy profiles and reduced side effects. Healthcare providers increasingly rely on these therapeutic agents as part of comprehensive treatment protocols for acute and chronic musculoskeletal conditions, driving sustained demand across hospitals, clinics, and outpatient facilities.
The growing prevalence of lifestyle-related muscle disorders, aging demographics, and expanding awareness of pain management alternatives continues to fuel market expansion, positioning muscle relaxant drugs as essential components in contemporary healthcare delivery systems worldwide.
Market Dynamics
The global muscle relaxant drugs market is propelled by several key drivers that collectively contribute to its robust growth trajectory, with the primary catalyst being the escalating prevalence of musculoskeletal disorders worldwide, driven by sedentary lifestyles, aging populations, and increasing incidence of workplace-related injuries that necessitate effective therapeutic interventions. The rising awareness among healthcare professionals and patients regarding advanced pain management strategies, coupled with continuous pharmaceutical innovations leading to the development of more targeted and efficacious muscle relaxant formulations with fewer adverse effects, significantly drives market expansion. Growing healthcare expenditure, improved insurance coverage for prescription medications, and expanding access to specialized medical care in emerging economies further accelerate market growth.
However, the market faces notable restraints including stringent regulatory frameworks governing drug approval processes, which can delay product launches and increase development costs, alongside growing concerns about potential abuse and dependency associated with certain muscle relaxant medications, leading to prescriber hesitancy and regulatory scrutiny. Patent expirations of blockbuster drugs create pricing pressures through generic competition, while alternative treatment modalities such as physical therapy, acupuncture, and non-pharmacological interventions may limit market penetration. Despite these challenges, the market presents substantial opportunities through the development of novel drug delivery systems including transdermal patches and extended-release formulations that enhance patient compliance and therapeutic outcomes.
Key Features of the Study
- This report provides in-depth analysis of the global muscle relaxant drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global muscle relaxant drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc., Tev Pharmaceutical Industries Ltd., Ipsen Pharma SA, Zydus Lifesciences Ltd., Neurana Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Johnson & Johnson Services Inc., Merck & Co., Inc., Eisai Co. Ltd., Intas Pharmaceuticals Ltd., Mallinckrodt PLC, Endo International plc, F. Hoffmann-La Roche AG, Merz Pharmaceuticals LLC, and Sun Pharmaceutical Industries Ltd
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global muscle relaxant drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global muscle relaxant drugs market
Market Segmentation
- Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Skeletal Muscle Relaxant Drugs (e.g., cyclobenzaprine, baclofen, etc.)
- Neuromuscular Blocking Agents (e.g., rocuronium, succinylcholine, etc.)
- Facial Muscle Relaxant Drugs (primarily botulinum toxin-based products like Botox, Dysport, Xeomin)
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Centrally Acting Muscle Relaxants
- Peripherally Acting Muscle Relaxants
- Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
- Tablet
- Capsule
- Liquid
- Others (Gel, Ointments and Sprays etc.)
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral (Injectables)
- Topical
- Application Insights (Revenue, USD Bn, 2020 - 2032)
- Muscle Spasm and Pain Relief
- Musculoskeletal Disorders
- Surgical Anesthesia
- Others (e.g., Fibromyalgia, etc.)
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adult
- Pediatric
- Geriatric
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Homecare
- Specialty Clinics
- Others
- Product Type Insights (Revenue, USD Bn, 2020 - 2032)
- Branded
- Generic
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Tev Pharmaceutical Industries Ltd.
- Ipsen Pharma SA
- Zydus Lifesciences Ltd.
- Neurana Pharmaceuticals Inc.
- Amneal Pharmaceuticals Inc.
- Johnson & Johnson Services Inc.
- Merck & Co., Inc.
- Eisai Co. Ltd.
- Intas Pharmaceuticals Ltd.
- Mallinckrodt PLC
- Endo International plc
- Hoffmann-La Roche AG
- Merz Pharmaceuticals LLC
- Sun Pharmaceutical Industries Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Muscle Relaxant Drugs Market, By Drug Type
- Global Muscle Relaxant Drugs Market, By Drug Class
- Global Muscle Relaxant Drugs Market, By Dosage Form
- Global Muscle Relaxant Drugs Market, By Route of Administration
- Global Muscle Relaxant Drugs Market, By Application
- Global Muscle Relaxant Drugs Market, By Age Group
- Global Muscle Relaxant Drugs Market, By Distribution Channel
- Global Muscle Relaxant Drugs Market, By End User
- Global Muscle Relaxant Drugs Market, By Product Type
- Global Muscle Relaxant Drugs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Muscle Relaxant Drugs Market, By Drug Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Skeletal Muscle Relaxant Drugs (e.g., cyclobenzaprine, baclofen, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Neuromuscular Blocking Agents (e.g., rocuronium, succinylcholine, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Facial Muscle Relaxant Drugs (primarily botulinum toxin-based products like Botox, Dysport, Xeomin)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Muscle Relaxant Drugs Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Centrally Acting Muscle Relaxants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Peripherally Acting Muscle Relaxants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Muscle Relaxant Drugs Market, By Dosage Form, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Tablet
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Capsule
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Liquid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Gel, Ointments and Sprays etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Muscle Relaxant Drugs Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral (Injectables)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Muscle Relaxant Drugs Market, By Application, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Muscle Spasm and Pain Relief
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Musculoskeletal Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Surgical Anesthesia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (e.g., Fibromyalgia, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Muscle Relaxant Drugs Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Muscle Relaxant Drugs Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Muscle Relaxant Drugs Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Homecare
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
12. Global Muscle Relaxant Drugs Market, By Product Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
13. Global Muscle Relaxant Drugs Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
14. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Tev Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ipsen Pharma SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zydus Lifesciences Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Neurana Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amneal Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson Services Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eisai Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Intas Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mallinckrodt PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Endo International plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merz Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
15. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
16. References and Research Methodology
- References
- Research Methodology
- About us
